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Abstract
Objective: An association between maternal HELLP syn-
drome and fetal long chain 3-hydroxyacyl-CoA dehydro-
genase (LCHAD) deficiency has been proposed. LCHAD
catalyzes the third step in the b-oxidation of fatty acids
in mitochondria. Whereas about 75% of LCHAD-deficient
patients carry a G-to-C mutation at nucleotide position
1528 (Glu474Gln, E474Q) on both chromosomes, com-
pound heterozygosity for E474Q on one chromosome
and a second different LCHAD mutation on the other can
be observed in up to 25% of LCHAD-deficiency cases;
only very few patients carry two mutations different from
E474Q. Genetic analysis of the mother alone is insuffi-
cient in case of compound heterozygosity. Since infor-
mation on the fetal carrier status of the E474Q mutation
in maternal HELLP syndrome is rare, we investigated the
frequency of the E474Q mutation in families where the
mother had HELLP syndrome.
Methods: The occurrence of the E474Q mutation was
analyzed by PCR and RFLP in 103 mothers with HELLP
syndrome, in 82 children of affected pregnancies and in
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21 fathers in families where fetal DNA was not available.
In addition, 103 control women with only uncomplicated
pregnancies were investigated.
Results: The mutation E474Q was not detected in the
study population.
Conclusion: Neither maternal nor fetal heterozygosity for
the E474Q mutation is a relevant factor of HELLP
syndrome.
Keywords: Fatty acid oxidation; HELLP syndrome; inher-
ited metabolic disease; 3-hydroxyacyl-CoA dehydrogen-
ase (LCHAD).
HELLP syndrome complicates 0.17–0.85% of all live
births and is a multisystem disorder specific to pregnan-
cy with a high maternal and perinatal morbidity and mor-
tality w7x. The pathogenesis of HELLP syndrome remains
incompletely understood, but in mothers of children suf-
fering from a fatty acid oxidation disorder with a long
chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) defi-
ciency, an increased incidence of HELLP syndrome or
acute fatty liver of pregnancy (AFLP) has been observed
w3, 9x. Ibdah et al. w3x published data on 19 pregnancies
with LCHAD-deficient fetuses, 16% of which were com-
plicated by HELLP syndrome and 63% by AFLP. These
findings suggest that the fetal condition may contribute
to the etiology of HELLP syndrome.
LCHAD catalyzes the third step in the b-oxidation of
fatty acids in mitochondria. The active site of this enzyme
is located in the C-terminal domain of each of the four
a-subunits of the trifunctional protein that is associated
with the inner mitochondrial membrane w10x. The gene
encoding for the a-subunit is localized in the chromo-
somal region 2p23. Eighty-seven percent of LCHAD-defi-
cient patients carry a G-to-C mutation at nucleotide
position 1528, resulting in an E474Q (Glu474Gln) amino
acid substitution w5x. The E474Q mutation inactivates
LCHAD directly within the catalytic domain and hetero-
zygosity reduces LCHAD activity in all organs by 50% w4,
8x. It was hypothesized that in the presence of the E474Q
mutation, long-chain 3-hydroxyacyl metabolites pro-
duced by the fetus or placenta can accumulate in the
mother and exert highly toxic effects on the liver, resulting
in the typical histological pattern found in HELLP syn-
drome or AFLP w3, 4x.
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Most studies on the correlation between maternal liver
disease in pregnancy and LCHAD deficiency focussed
only on the maternal genotype with the exception of
Yang et al. w11x who screened 27 women with AFLP and
81 with HELLP syndrome recruited in North-America and
their offspring or partners for mutations in the TFP
a-subunit. They identified E474Q as an important risk
factor for AFLP (19% carriers) but not for HELLP syn-
drome (1.23%). The ethnic background of the study pop-
ulation was mixed and entry criteria were not strictly
defined.
The aim of our study was to assess the frequency of
the E474Q mutation in Caucasian families where the
mother had been affected by HELLP syndrome but not
AFLP in at least one pregnancy. We performed molecular
genetic analysis in 103 Caucasian women with clearly
defined HELLP syndrome, their offspring or partner. The
diagnosis of HELLP syndrome was based on the pres-
ence of hemolytic anemia (serum haptoglobin levels
-0.3 g/L or LDH)300 U/L), elevated liver enzymes (ele-
vation of AST or ALT over norm), and evidence of throm-
bocytopenia, defined as a platelet count of -100.000/
mL. In addition to the mothers, we tested either their
children born from pregnancies complicated by HELLP
syndrome (ns82) or, if the child’s blood was not availa-
ble, the fathers (ns21) for the E474Q mutation. In addi-
tion, 103 unrelated female probands of German origin
with uncomplicated pregnancies served as controls. The
study was approved by the Institutional Medical Ethics
Committee (EK 934) and informed consent was obtained
from adult subjects and parents of the children. Genomic
DNA was isolated from venous blood or umbilical cord
blood samples, respectively, as described by Miller et al.
w6x.
To allow rapid genotyping, a PCR-based restriction
fragment length polymorphism (RFLP) assay for the var-
iant E474Q, based on an MspI digest, was established.
Since the wildtype DNA sequence does not contain the
respective restriction site, we constructed a mismatch
primer. Primer sequences were as follows: sense pri-
mer is 59-T-CCC-GTG-GAC-AAG-ATG-CAG-CTG-CCI G-
39 (artificially created restriction site for MspI is under-
lined), antisense primer sequence is 59-CTG-CAG-CTC-
TGT-TAT-ACA-GCC-39. In case of the wildtype sequence,
MspI digests the 145 bp-product into two fragments (122
and 23 bp), in case of E474Q mutation this restriction
site is destroyed and the amplification product remains
undigested (145 bp). PCR and restriction analysis were
carried out according to standard protocols. Digestion
products were separated on 10% polyacrylamide gels,
further details can be provided on request. Bands were
visualized by silver staining.
None of the 103 HELLP patients, 82 fetuses, 21
fathers, and none of the 103 controls showed heterozy-
gosity for the E474Q mutation. Our results thus confirm
those of den Boer et al. w2x who found heterozygosity for
the E474Q mutation in one mother among 113 Dutch
women with a history of HELLP syndrome. Furthermore
our data are in accordance with those reported by Yang
et al. w11x. Among 81 North-American women with
HELLP syndrome they detected one mother who was
heterozygous for E474Q whereas no mutation was found
in the offspring. The study population was mostly of Cau-
casian descent, but African American and Hispanic wom-
en were also included.
According to Ijlst et al. w5x, about 75% of LCHAD defi-
cient children are homozygous for the E474Q mutation
while up to 25% carry a second mutation different from
E474Q, and very few LCHAD patients carry two muta-
tions other than E474Q. Thus, 50% of these compound
heterozygotes cannot be identified by analysis of the
mothers alone. We, therefore, examined either the off-
spring or the father, in addition to the mother, in order to
study the prevalence of fetal LCHAD deficiency among
women with HELLP syndrome. None of the children and
none of the fathers showed the E474Q mutation. Follow-
ing Hardy-Weinberg’s law, a negative result for the E474Q
mutation in the a-subunit of the TFP in both parents or
the fetus excludes this mutation as a major genetic risk
factor in an unselected obstetric population with HELLP
syndrome.
The role of other LCHAD mutations in the pathogene-
sis of HELLP syndrome should be further elucidated.
Mutation analysis among LCHAD-deficient patients reve-
aled at least 10 other mutations, apart from the common
E474Q mutation w3x. These non-E474Q mutations gen-
erate nonsense (premature termination) codons, either
directly or by causing frame shifts in the a-subunit mRNA
w8x. Yang et al. w11x screened the MTP a-subunit for
E474Q and other mutations by SSCP and direct
sequencing, but no further mutation, neither maternal nor
fetal, were found in women affected by HELLP syn-
drome. Recently, a novel a-subunit mutation in exon 11
of the LCHAD domain (Q322K) was described. The
mother who developed HELLP syndrome after delivery
was found to be heterozygous for this mutation while the
fetal genotype was completely normal w1x. Whether these
non-E474Q mutations, which usually occur in combina-
tion with the common E474Q mutation as the second
allele in LCHAD deficiency with the exception of the case
mentioned above, play a crucial role in the development
of HELLP syndrome in the general obstetric population
has yet to be investigated.
The comparison of our study with the Dutch study per-
formed by Den Boer et al. w2x, both with a similar ethnic
background, reveals a low prevalence of the E474Q
mutation among women with HELLP syndrome (1:216).
Thus, the carrier frequencies of this common LCHAD
mutation do not differ significantly from the general pop-
ulation (1:783) w2x. To conclude, our data do not provide
evidence for a relevant role of maternal or fetal hetero-
zygous E474Q LCHAD mutations in the pathogenesis of
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HELLP syndrome. Abnormal LCHAD function seems to
represent only one of a variety of risk factors in the eti-
ology of this specific disorder of pregnancy. Therefore,
future studies will have to concentrate on other candidate
genes that might be causative factors for HELLP syn-
drome. However, considering the clinical consequences
it is important to remember the risk of LCHAD deficiency
in a newborn of a mother with HELLP syndrome.
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